Indeed, the overexpression of this gene may cause a more aggressive phenotype, but it can also render the tumor more sensitive to EGFR antagonists, such as erlotinib and the monoclonal antibody against EGF cetuximab, which have proved to be effective in reducing proliferation in vitro using CCA-derived lines [114]. Here, EGFR is linked to neoplasm.